Evidence map›Paper›PMID 32132525›Full record

ArticleNature communications2020

A generalizable 29-mRNA neural-network classifier for acute bacterial and viral infections.

Michael B Mayhew, Ljubomir Buturovic, Roland Luethy, Uros Midic, Andrew R Moore, Jonasel A Roque, Brian D Shaller, Tola Asuni, David Rawling, Melissa Remmel and 5 more

Abstract readEvaluation Study
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Michael B MayhewInflammatix, Inc., 863 Mitten Rd, Suite 104, Burlingame, CA, 94010, USA.
Ljubomir ButurovicInflammatix, Inc., 863 Mitten Rd, Suite 104, Burlingame, CA, 94010, USA.
Roland LuethyInflammatix, Inc., 863 Mitten Rd, Suite 104, Burlingame, CA, 94010, USA.
Uros MidicInflammatix, Inc., 863 Mitten Rd, Suite 104, Burlingame, CA, 94010, USA.
Andrew R MooreDepartment of Medicine, Stanford University, Palo Alto, CA, 94305, USA.ORCID http://orcid.org/0000-0001-8040-2576
Jonasel A RoqueDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Stanford University, Palo Alto, CA, 94305, USA.ORCID http://orcid.org/0000-0001-7818-6958
Brian D ShallerDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Stanford University, Palo Alto, CA, 94305, USA.
Tola AsuniDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Stanford University, Palo Alto, CA, 94305, USA.
David RawlingInflammatix, Inc., 863 Mitten Rd, Suite 104, Burlingame, CA, 94010, USA.
Melissa RemmelInflammatix, Inc., 863 Mitten Rd, Suite 104, Burlingame, CA, 94010, USA.
Kirindi ChoiInflammatix, Inc., 863 Mitten Rd, Suite 104, Burlingame, CA, 94010, USA.
James WackerInflammatix, Inc., 863 Mitten Rd, Suite 104, Burlingame, CA, 94010, USA.
Purvesh KhatriInstitute for Immunity, Transplantation and Infections, Stanford University, Palo Alto, CA, 94305, USA.ORCID http://orcid.org/0000-0002-4143-4708
Angela J RogersDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Stanford University, Palo Alto, CA, 94305, USA.
Timothy E SweeneyInflammatix, Inc., 863 Mitten Rd, Suite 104, Burlingame, CA, 94010, USA. tsweeney@inflammatix.com.ORCID http://orcid.org/0000-0002-3596-1093

Funding

Translational Incubator CoreU19AI109662 · NIAID · STANFORD UNIVERSITY · PI GLENN, JEFFREY S · 2014 to 2019
$28.6M
Metabolic derangements in ARDSK23HL125663 · NHLBI · STANFORD UNIVERSITY · PI ROGERS, ANGELA J · 2015 to 2018
$744k
NHLBI NIH HHS K23 HL125663NIAID NIH HHS U19 AI109662
6 · The paper itself

Abstract

Improved identification of bacterial and viral infections would reduce morbidity from sepsis, reduce antibiotic overuse, and lower healthcare costs. Here, we develop a generalizable host-gene-expression-based classifier for acute bacterial and viral infections. We use training data (N = 1069) from 18 retrospective transcriptomic studies. Using only 29 preselected host mRNAs, we train a neural-network classifier with a bacterial-vs-other area under the receiver-operating characteristic curve (AUROC) 0.92 (95% CI 0.90-0.93) and a viral-vs-other AUROC 0.92 (95% CI 0.90-0.93). We then apply this classifier, inflammatix-bacterial-viral-noninfected-version 1 (IMX-BVN-1), without retraining, to an independent cohort (N = 163). In this cohort, IMX-BVN-1 AUROCs are: bacterial-vs.-other 0.86 (95% CI 0.77-0.93), and viral-vs.-other 0.85 (95% CI 0.76-0.93). In patients enrolled within 36 h of hospital admission (N = 70), IMX-BVN-1 AUROCs are: bacterial-vs.-other 0.92 (95% CI 0.83-0.99), and viral-vs.-other 0.91 (95% CI 0.82-0.98). With further study, IMX-BVN-1 could provide a tool for assessing patients with suspected infection and sepsis at hospital admission.

Indexed as

Neural Networks, ComputerAcute DiseaseAdultAgedAged, 80 and overBacterial InfectionsDatasets as TopicFemaleGene Expression ProfilingHospital MortalityHost-Pathogen InteractionsHumansIntensive Care UnitsMaleMiddle AgedRNA, MessengerRNA, Messenger

Identifiers

PMID32132525
PMCPMC7055276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.